Apple Health Outcome
4 compoundsin Regimen’s catalog are configured to track glucose via Apple Health. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.
The GLP-1 receptor agonist class was developed initially for type 2 diabetes — weight loss was the secondary effect that drove the modern adoption wave. The class lowers blood glucose through three mechanisms: glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, and slowed gastric emptying that flattens the postprandial glucose curve.
In the LEADER trial, liraglutide reduced HbA1c by 1.4 percentage points and produced a 13% reduction in major adverse cardiovascular events over 3.8 years. Semaglutide and tirzepatide produce larger HbA1c reductions — typically 1.5–2.0 percentage points — and tirzepatide’s addition of GIP agonism appears to amplify the insulin-secretory response.
Continuous glucose monitoring (CGM) is increasingly used alongside GLP-1 protocols to visualize the day-to-day glucose curve. Apple Health stores CGM readings from compatible devices, and Regimen surfaces them alongside dose history on each protocol.
Anchor citation: Marso SP et al.. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine, 2016.
4 compounds
GLP-1 Receptor Agonist
A once-weekly GLP-1 receptor agonist for weight management and metabolic health.
Tracks
GIP / GLP-1 Dual Agonist
A once-weekly dual GIP and GLP-1 receptor agonist delivering superior weight loss and metabolic improvements compared to GLP-1 monotherapy.
Tracks
GLP-1 Receptor Agonist (Saxenda / Victoza)
Daily injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza, up to 1.8 mg/day) and chronic weight management (Saxenda, up to 3.0 mg/day). Slows gastric emptying, increases satiety, improves glycemic control, and reduces cardiovascular events in T2D.
Tracks
Rapid-Acting Insulin (clinical reference)
Pre-dissolved at U-100 concentration (100 IU/mL). Units on a U-100 insulin syringe map 1:1 to draw volume in mL × 100. Insulin is FDA-approved for diabetes management and must be used under medical supervision. Off-label use for nutrient partitioning carries severe hypoglycemia risk and is not recommended.
Tracks
GLP-1s are glucose-dependent — they only stimulate insulin secretion when blood glucose is elevated. As monotherapy, the hypoglycemia risk is very low. The risk rises when GLP-1s are combined with insulin or sulfonylureas, which work through glucose-independent mechanisms; in those cases the GLP-1 dose is typically adjusted downward.
HbA1c reflects an 8–12 week glucose average, so the lab-measured change appears 8–12 weeks after dose escalation. Day-to-day glucose readings (CGM, fingerstick) drop within days of starting an effective dose. The full HbA1c response in the SUSTAIN and SURPASS trials was typically reached by week 26–40.
Regimen reads glucose from Apple Health, which integrates with Dexcom, Libre, and Stelo CGMs. The glucose readings appear on the protocol’s Tracked Outcomes view next to your dose log, so you can see whether your fasting and postprandial numbers are trending downward as you titrate the dose.
Related reading
Best peptide tracker app in 2026
An honest multi-protocol comparison of Regimen, PeptIQ, Shotsy, MeAgain, and the GLP-1 calculator apps.
Other outcomes